After IPO, BridgeBio Looks To Tuck Eidos Back Into Its Flock

Is Eidos a goose that could lay a golden egg? BridgeBio wants to own it all, instead of two-thirds, in case its subsidiary's lead program in TTR amyloidosis succeeds in Phase III.